Guanhao Biotech Co Ltd

Guanhao Biotech Co Ltd has a market capitalization of 3.47 billion CNY and a price-to-earnings ratio of 142.56, indicating a high valuation relative to its earnings. The company's liquidity position is characterized as medium, with a current ratio of 1.73, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's free cash flow is negative at -1.85 million CNY, and its capital expenditure is -38.17 million CNY, indicating significant investment in long-term assets. In terms of profitability, Guanhao Biotech Co Ltd has a return on equity of 4.27% and a return on assets of 3.02%, which are below the industry median for medical equipment and supplies companies. The company's gross profit margin is 76.64%, and its operating margin is 7.83%, both of which are key metrics for assessing the efficiency of its operations. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification could expose the company to higher risks if demand in its primary market fluctuates. The company's debt-to-equity ratio is 0.22, indicating a relatively low level of leverage compared to industry peers. Looking ahead, the company's revenue is projected to grow, with a positive outlook for the current fiscal year. However, the exact growth rate is not specified in the available data. The company's capital expenditure is expected to remain a significant portion of its operating cash flow, which could impact its ability to fund other growth initiatives. The risk assessment for Guanhao Biotech Co Ltd highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could affect its financial flexibility. There are no recent events or filings that indicate significant changes in the company's financial or operational status.